



GoConnect Limited
ACN 089 240 353
1st Floor, 237 East Boundary
Road, Bentleigh East VIC 3165
Australia
Tel: 61 3 8833 7242

30 October 2023

Ryan Marshall
National Stock Exchange of Australia Limited
1 Bligh Street
Sydney NSW 2000

Dear Ryan,

We refer to your letter today to our company **Re: Price Movement and Volume Query**, and we respond as follows:

Re Q1: No.

Re Q2: Not applicable.

Re Q3: We would like to refer you to the Media Release from COVIRIX Medical Pty Ltd first released to the NSX on 30 March 2023. See attached Media Release again. Subsequent to the publication of the Media Release on the NSX Announcement Platform, this Release has been widely circulated around the world to mainstream and social media.

In this release, COVIRIX Medical advises that, IP Australia has granted a 20 years patent for the company's repurposed antiviral treatment and prevention of pulmonary infections. The antiviral treatment of COVIRIX Medical is designed to be administered by oral inhalation which COVIRIX Medical believes will provide a targeted treatment solution for COVID-19, which offers the prospect of faster onset of action and reduced side effects compared to systemic (oral) drugs.

In granting the Australian patent, The Australian Patent Office (IP Australia) has accepted that the company's invention is novel, inventive, and patentable. COVIRIX Medical has proceeded to file further patent applications based on its international (Patent Cooperation Treaty) patent application in a number of significant offshore jurisdictions namely the US, EU, China, and Japan to seek patent protection for the company's invention.

Furthermore COVIRIX Medical also advises that:

COVIRIX is pleased to be able to contribute to the arsenal of therapeutics to be used by the global healthcare system to help in the treatment of COVID-19. Since our drug candidates are broad spectrum in nature, they will possibly also be applicable to a range of other respiratory diseases.

GoConnect Ltd ("GO8") holds 43.6% of Go Green Holdings Ltd ("GGH") which in turn is a 24% shareholder in COVIRIX Medical.

We believe this Media Release highlights a very significant milestone and accordingly, the much improved enterprise value that COVIRIX Medical has achieved which therefore, has contributed to the increasing level of investor interest in GO8 shares. GO8 is the only company listed through which public investors can participate in COVIRIX Medical.

In recent weeks the crypto currency market has been trending positively with the prospect of the US SEC approval of a number of Spot Bitcoin ETF investment products providing much optimism to investors. These ETF products are being launched by some of the world's largest asset managers including BlackRock, Fidelity, Ark Invest, etc. The Bitcoin price has risen sharply from the June low of about US\$25,000 to the current market price of about US\$35,000. Projections reported of the Bitcoin price reaching over US\$100,000 by 2024 have also fuelled much buying speculation.

GGH has significant direct and indirect holdings in Zucoins: total of 61,700 Zucoins: consisting of 40,000 Zucoins owned directly by GGH, 80,000 Zucoins owned by Covirix Medical, 10,000 Zucoins owned by Global Diabetes Solutions. As advised by Zucoins, Zucoins token is to be trading on the "Zutopia" platform, facilitated by Visa Card, by end of November 2023. Zucoins according to Zucoins, is targeting in the long term to reach 20% of the Bitcoin market price with many of its features superior to that of Bitcoin. It will certainly be interesting to see if Zucoins can deliver its promised returns upon listing.

Re Q4: Yes.

Yours faithfully

A handwritten signature in black ink, appearing to read 'Richard Li', with a large, sweeping initial stroke.

Richard Li
Executive Chairman